'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026
Table of Contents
The 'Exercise in a Pill' Wave Hits the Mainstream
This week STAT reported on a milestone that the peptide community has watched coming for two years: peptides and peptide-adjacent 'research compounds' are going mainstream, tracing how BPC-157 jumped from a Croatian lab to bodybuilding forums to the FDA's regulatory agenda. The same migration is now visible in a different corner of the market — metabolic and 'exercise mimetic' compounds that promise the benefits of training, fat loss, and longevity without an incretin drug's appetite suppression. Three names dominate the conversation in June 2026: SLU-PP-332, an ERR pan-agonist marketed as 'exercise in a pill'; 5-Amino-1MQ, an NNMT inhibitor sold for fat metabolism; and MOTS-c, a mitochondrial-derived peptide. All three are now offered direct-to-consumer through the same channels that sell GLP-1 analogs and healing peptides — and all three rest on almost entirely preclinical evidence. For consumers and clinicians, the most important fact is the one most often skipped: these compounds work through completely different mechanisms, sit in different regulatory buckets, and carry very different levels of human data.
SLU-PP-332: An ERR Agonist That Mimics Endurance Training
SLU-PP-332 is the newest of the three to gain real traction. It is a small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ) — orphan nuclear receptors that act as master switches for mitochondrial biogenesis and oxidative metabolism. The 'SLU' in its name reflects its Saint Louis University origin, where it was first characterized by Thomas Burris and colleagues. In mice, SLU-PP-332 increased fast oxidative (Type IIa) muscle fibers, fatty-acid oxidation, and treadmill endurance in an ERRα-dependent way; in metabolic-syndrome models it raised energy expenditure and improved insulin sensitivity and reduced fat mass without the animals eating less. That mechanism is why it is marketed as an 'exercise mimetic.' Two cautions matter. First, despite the hype, there are no published human clinical trials of SLU-PP-332 as of June 2026 — every efficacy claim traces back to cell or rodent work. Second, and tellingly, anti-doping laboratories have already published methods to detect SLU-PP-332 and its metabolites. Detection assays don't get built for compounds nobody is using; they get built because athletes are already taking it. Critically, SLU-PP-332 is a small molecule, not a peptide, and it is not among the seven peptides the FDA will review for compounding in July — so no realistic regulatory pathway legitimizes it in the near term.
5-Amino-1MQ and MOTS-c: Same Marketing Shelf, Different Mechanisms
It is easy to lump these compounds together because they share suppliers and a longevity-and-metabolism pitch, but they are mechanistically distinct. 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT); by blocking NNMT it is proposed to raise intracellular NAD+ (by up to ~40% in the foundational 2018 work) and shift fat cells toward energy expenditure. Like SLU-PP-332, it is not a peptide and has no completed large-scale human trials. MOTS-c, by contrast, is a genuine mitochondrial-derived peptide — a 16-amino-acid peptide encoded in mitochondrial DNA that regulates metabolic homeostasis and has been studied for obesity and osteoporosis-related endpoints. The practical takeaway for buyers: 'NAD+ booster,' 'exercise mimetic,' and 'mitochondrial peptide' are not interchangeable. They hit different targets (NNMT vs. ERR vs. mitochondrial signaling), and only one of the three — MOTS-c — is even a peptide.
Why the July PCAC Vote Won't Cover All of Them
The FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to decide whether seven research peptides — BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP — should be added to the 503A Bulks List, the first potential regulatory green light for compounded research peptides in years. MOTS-c is on that list; a favorable vote could move it from gray-market 'research use only' status toward legitimate pharmacy compounding. But here is the distinction that gets lost in the excitement: SLU-PP-332 and 5-Amino-1MQ are NOT on the PCAC list. They are small molecules, not peptides, and they are not part of this review at all. Even a unanimous yes vote in July would do nothing to legitimize them. Buyers who assume 'the FDA is reviewing peptides in July, so these are about to be approved' are conflating three different regulatory categories — FDA-approved drugs, potentially-compoundable peptides under PCAC review, and unregulated research chemicals that no current process touches. The public comment docket (FDA-2025-N-6895) closes ahead of the meeting, and a second PCAC covering additional peptides is expected by early 2027.
What to Watch and How to Read the Evidence
For anyone tracking this space, three things are worth watching through the second half of 2026. First, human data: SLU-PP-332's entire case is preclinical, and the first credible human pharmacokinetic or safety study would meaningfully change its risk profile in either direction. Second, the muscle-preservation angle — as GLP-1 and amylin therapies drive large weight loss, lean-mass loss is a recognized problem, and ERR agonists are being discussed as a way to preserve oxidative muscle quality; whether that hypothesis survives contact with human trials is an open question. Third, the regulatory line: the July PCAC vote will sharpen, not blur, the divide between peptides on a compounding pathway (like MOTS-c) and research chemicals that remain outside any framework (like SLU-PP-332 and 5-Amino-1MQ). The recurring consumer-education point holds: provenance and evidence level are everything. A pharmacy-compounded peptide dispensed against a prescription and a vial of the same-named compound bought as a 'research chemical' are not the same product, and a compound being popular — even popular enough that anti-doping labs build tests for it — is not the same as a compound being proven safe in humans.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] STAT — An obesity drug deep-dive, and peptides move mainstream (June 11, 2026) Source
- [2] Billon C. et al. — A synthetic ERR agonist (SLU-PP-332) alleviates metabolic syndrome (ScienceDirect, 2024) Source
- [3] Chemical optimization of the exercise mimetic SLU-PP-332 — estrogen-related receptor signaling (PMC, 2026) Source
- [4] In Vitro Metabolites of Exercise Mimetic SLU-PP-332 for Doping-Control Purposes (PubMed, 2026) Source
- [5] Neelakantan H. et al. — Selective small-molecule inhibitors of NNMT (5-Amino-1MQ), Biochem Pharmacol 2018 Source
- [6] FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting Source
- [7] FDA's Pep(tide) Rally! What Compounders and Industry Need to Know — FDA Law Blog Source
Related Articles
The FDA formally removes 12 peptides from Category 2 ahead of July PCAC hearings, LL-37 derivative research achieves improved stability and efficacy, dihexa produces measurable synaptogenesis in non-human primates, pentosan polysulfate shows 6-month disease modification in OA, and DSIP fusion peptides cross the blood-brain barrier.
The FDA confirms its July 23–24 PCAC meeting will review BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP for 503A compounding eligibility. A landmark NEJM trial shows tirzepatide outperforms semaglutide by 6.5 percentage points in weight loss. Viking completes VANQUISH-2 enrollment for VK2735, and researchers identify CAP-GDF15 as a new appetite-suppressing peptide from the GDF15 propeptide region.
Telehealth platforms are racing to own regulated peptide supply chains ahead of the FDA's July 23–24 PCAC vote. Noom has acquired 503A pharmacy Tailor Made Compounding to add sermorelin and NAD+ to its formulary, following Hims & Hers' peptide facility purchase. Meanwhile, Eli Lilly's selective amylin agonist eloralintide enters its combination era with a tirzepatide pairing trial reading out late 2026.